Fatal pulmonary toxicity resulting from treatment with gemcitabine
نویسندگان
چکیده
منابع مشابه
Pulmonary toxicity associated with gemcitabine.
Gemcitabine (2’,2’-difluoro-s’-deoxycytidine; Gemzar, Eli Lilly, Indianapolis, IN, USA), a pyrimidine nucleoside analogue similar to cytarabine, inhibits DNA synthesis both by halting DNA replication through the incorporation of its active form into DNA and also by inhibiting ribonucleotide reductase and deoxycytidine monophosphate deaminase [1, 2]. It is administered as a prodrug that becomes ...
متن کاملGemcitabine-induced pulmonary toxicity.
BACKGROUND Gemcitabine is the only approved cytotoxic agent for the treatment of pancreatic cancer by the Food and Drug Administration. In addition, gemcitabine is also commonly used for the management of breast, ovarian, and non-small cell lung cancer. Myelosuppression is the most common toxicity of gemcitabine therapy. Pulmonary toxicities due to gemcitabine have, however, been reported. Dysp...
متن کاملGemcitabine Induced Pulmonary Toxicity with Late Onset
Gemcitabine is a nucleoside analog that has been increasingly used in the chemotherapy of solide tumors, including breast, pancreas ovary and non small cell lung cancer. It is generally well tolerated and has few side effects. Gemcitabine induced pulmonary complications range from mild dyspnea to death from ARDS. A 57yearold man was treated with six cycles of gemcitabine because of pancreatic c...
متن کاملAn autopsy case of acute pulmonary toxicity associated with gemcitabine.
Acute respiratory distress syndrome (ARDS) developed following intravenous gemcitabine monotherapy in a 75-year-old man with non-small cell lung cancer. The total dose of gemcitabine was 1,500 mg, and the latent period from starting gemcitabine to pulmonary toxicity was three days. The chest radiographs and high resolution computed tomographic scan revealed bilateral ground-glass opacity. He di...
متن کاملGemcitabine-induced pulmonary toxicity in a patient with pancreatic cancer.
We previously read with interest the article by Shaib et al. on gemcitabine-induced pulmonary toxicity during adjuvant therapy in a patient with pancreatic cancer [1]. We would like to share our experience. A 74-year-old woman was referred to our hospital with a 23x19 mm pancreatic body tumor with dilatation of pancreatic duct which was detected incidentally and was diagnosed with pancreatic ca...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer
سال: 1998
ISSN: 0008-543X,1097-0142
DOI: 10.1002/(sici)1097-0142(19980501)82:9<1802::aid-cncr33>3.0.co;2-6